Latest Healthcare It News

Synlait has agreed to sell its North Island assets to global healthcare giant Abbott for approximately US$178 million, marking a strategic reset focused on debt reduction and operational simplification. The deal, expected to close by April 2026, positions Synlait to concentrate on its South Island operations and explore new growth avenues.

Elanor Investors Group has obtained a crucial ASX waiver allowing a longer timeframe to issue securities tied to its $125 million recapitalisation with Rockworth Investment. This move addresses regulatory delays and aims to stabilise Elanor's balance sheet and reduce gearing.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

XRF Scientific Limited has confirmed its fully franked ordinary dividend for the 2025 financial year and updated details of its Dividend Reinvestment Plan price, offering shareholders a clear view on income and reinvestment options.

INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.

IMEXHS Limited has secured a significant one-year contract with Colombian cancer care provider Oncolife to deliver advanced radiology services, leveraging its integrated software and AI tools to enhance diagnostic precision.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.

Invex Therapeutics has voluntarily suspended trading on the ASX pending a significant acquisition announcement and responses to a price query. The suspension is expected to last until the announcement or early next week.

Sonic Healthcare announces a major leadership transition with Dr Colin Goldschmidt retiring after 32 years as CEO, succeeded by Dr Jim Newcombe. The company also appoints Evangelos Kotsopoulos as Chief Operating Officer to support its global growth ambitions.

Cann Group Limited has reported its first-ever EBITDA-positive month in August 2025, driven by strong B2B flower sales and disciplined cost management. The company is advancing export negotiations in Europe and preparing to launch a new Botanitech product range.

Vitura Health Limited has updated its dividend distribution details, confirming a fully franked ordinary dividend and issuing nearly 487,000 new shares under its Dividend Reinvestment Plan.